Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245423 | 0.94 | CASP3 (0.45) | PDE4BPLAUPLATMAPKAPK2CASP3 | |
| SCHEMBL12694092 | 0.88 | PLAU (0.40) | PLAUPLATMAPKAPK2CASP3SENP8 | |
| SCHEMBL1829684 | 0.83 | HRH2 (0.45) | MAPKAPK2GABRPGABRDCYP1A2CYP2D6 | |
| SCHEMBL244388 | 0.82 | PLAU (0.40) | PLAUPLATMAPKAPK2CYP2C19CHEK2 | |
| SCHEMBL246204 | 0.82 | PLAU (0.40) | PLAUPLATMAPKAPK2CYP2C19CHEK2 | |
| Bicarbonate SCHEMBL12521326 | 0.82 | PLAU (0.42) | PLAUPLATMAPKAPK2CHEK2CA1 | |
| SCHEMBL244821 | 0.82 | PLAU (0.40) | PLAUPLATMAPKAPK2CHEK2CA1 | |
| SCHEMBL246155 | 0.81 | PLAU (0.41) | PLAUPLATMAPKAPK2CHEK2CA1 | |
| SCHEMBL244538 | 0.79 | MAPKAPK2 (0.38) | PLAUPLATMAPKAPK2CHEK2CA1 | |
| SCHEMBL248063 | 0.79 | PLAU (0.38) | PLAUPLATMAPKAPK2CHEK2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | claimed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | claimed |
| US-8642628-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | claimed |
| EP-2315590-B1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS LLC (US) | 2012-09-26 | — | — | EP | claimed |
| JP-2012500218-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | claimed |
| EP-2315590-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, LLC (US) | 2011-05-04 | — | — | EP | claimed |
| WO-2010019909-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | claimed |
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2315590-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010019909-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019909-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | PDE4B 1767/4885PLAU 3061/4885PLAT 3217/4885 |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | PDE4B 1767/4885PLAU 3061/4885PLAT 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.